MedTrace Logo

Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma (NPC)

NCT03682055 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2023-08-15

Study results available
· View outcomes & findings →

Summary

VK-2019-001 is a 1/2a trial of the oral EBNA-1 targeting agent VK-2019 in patients with EBV-positive recurrent or metastatic NPC to determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D), as well as to evaluate the PK profile of VK-2019.

Conditions

  • Nasopharyngeal Carcinoma
  • Nasopharyngeal Cancer

Interventions

DRUG

VK-2019

EBNA1 inhibitor

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Cullinan Therapeutics Inc.

    lead INDUSTRY

Principal Investigators

  • A. Dimitrios Colevas, MD · Stanford Cancer Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-04
Primary Completion
2020-06-23
Completion
2020-08-08
FDA Drug
Yes

Countries

  • United States
  • China
  • France
  • Hong Kong
  • Singapore

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03682055 on ClinicalTrials.gov